Advisors Asset Management Inc. Has $714,000 Holdings in Vericel Co. (NASDAQ:VCEL)

Advisors Asset Management Inc. raised its position in Vericel Co. (NASDAQ:VCEL) by 4.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 16,890 shares of the biotechnology company’s stock after purchasing an additional 644 shares during the period. Advisors Asset Management Inc.’s holdings in Vericel were worth $714,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of VCEL. Global Alpha Capital Management Ltd. raised its position in Vericel by 60.2% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 23,383 shares of the biotechnology company’s stock valued at $988,000 after buying an additional 8,791 shares during the last quarter. Segall Bryant & Hamill LLC grew its stake in shares of Vericel by 49.2% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 115,334 shares of the biotechnology company’s stock worth $4,873,000 after acquiring an additional 38,031 shares in the last quarter. Premier Fund Managers Ltd acquired a new stake in shares of Vericel in the third quarter valued at approximately $781,000. Meeder Asset Management Inc. bought a new stake in shares of Vericel in the third quarter worth $92,000. Finally, RiverPark Advisors LLC boosted its holdings in Vericel by 124.5% during the third quarter. RiverPark Advisors LLC now owns 5,572 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 3,090 shares during the last quarter.

Vericel Price Performance

VCEL stock opened at $58.75 on Wednesday. Vericel Co. has a one year low of $32.31 and a one year high of $61.49. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of 979.17 and a beta of 1.66. The company has a fifty day moving average price of $46.69 and a two-hundred day moving average price of $47.14.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.03. The business had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. Research analysts anticipate that Vericel Co. will post 0.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on VCEL. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Vericel in a research note on Friday, November 8th. Canaccord Genuity Group started coverage on Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 target price on the stock. TD Cowen raised their price target on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. Stephens upped their price objective on Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $60.00 target price on shares of Vericel in a research note on Tuesday, November 19th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.71.

Insider Transactions at Vericel

In related news, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. This trade represents a 7.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total transaction of $235,361.55. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at $443,850. This represents a 34.65 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,666 shares of company stock worth $1,350,764. Company insiders own 5.20% of the company’s stock.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.